Industry Exchange Workshop on Food and Drug Administration Drug and Device Requirements; Public Workshop, 43141-43142 [E9-20340]
Download as PDF
43141
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
prospective candidates should be sent to
FDA by September 25, 2009.
ADDRESSES: All nominations for
membership should be sent
electronically to cv@oc.fda.gov, or by
mail to Advisory Committee Oversight &
Management Staff, 5600 Fishers Lane
(HF–4), rm. 14C03, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT: Erik
P. Mettler, Office of Policy, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, rm. 4324, Silver Spring,
MD 20993, 301–796–4711, FAX: 301–
847–3541, e-mail:
erik.mettler@fda.hhs.gov.
The
agency requests nominations for
nonvoting industry representatives on
the Tobacco Products Scientific
Advisory Committee. Elsewhere in this
issue of the Federal Register, FDA is
publishing two separate documents
announcing the establishment of the
committee and the request for
nomination of the Tobacco Products
Scientific Advisory Committee.
SUPPLEMENTARY INFORMATION:
I. Center for Tobacco
Tobacco Products Scientific Advisory
Committee
jlentini on DSKJ8SOYB1PROD with NOTICES
The Tobacco Products Scientific
Advisory Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to the regulation of tobacco
products. The Committee reviews and
evaluates safety, dependence, and
health issues relating to tobacco
products and provides appropriate
advice, information, and
recommendations to the Commissioner
of Food and Drugs.
The Committee shall include three
nonvoting members who are identified
with industry interests. These members
shall include one representative of the
tobacco manufacturing industry, one
representative of the interests of tobacco
growers, and one representative of the
interests of the small business tobacco
manufacturing industry. This final
position can be filled on a rotating,
sequential basis by representatives of
different small business tobacco
manufacturers based on areas of
expertise relevant to the topics being
considered by the Committee.
CONTACT)
within 30 days of publication
of this document. Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations;
and a list of all nominees along with
their current resumes. The letter will
also state that it is the responsibility of
the interested organizations to confer
with one another and to select a
candidate, within 60 days after the
receipt of the FDA letter, to serve as the
nonvoting member to represent industry
interests for the Tobacco Products
Scientific Advisory Committee. The
interested organizations are not bound
by the list of nominees in selecting a
candidate. However, if no individual is
selected within 60 days, the
Commissioner of Food and Drugs will
select the nonvoting member to
represent industry interests.
III. Application Procedure
Individuals may self nominate and/or
an organization may nominate one or
more individuals to serve as a nonvoting
industry representative. A current
curriculum vitae and the name of the
committee of interest should be sent to
the FDA contact person within the 30
days. FDA will forward all nominations
to the organizations expressing interest
in participating in the selection process
for the committee. (Persons who
nominate themselves as nonvoting
industry representatives will not
participate in the selection process).
FDA has a special interest in ensuring
that women, minority groups,
individuals with physical disabilities,
and small businesses are adequately
represented on its advisory committees,
and therefore, encourages, nominations
for appropriately qualified candidates
from these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: August 19, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–20483 Filed 8–25–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Industry Exchange Workshop on Food
and Drug Administration Drug and
Device Requirements; Public
Workshop
AGENCY:
ACTION:
COST OF REGISTRATION
Any industry organization interested
in participating in the selection of an
appropriate nonvoting member to
represent industry interests should send
a letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
17:05 Aug 25, 2009
Notice of public workshop.
SUMMARY: The Food and Drug
Administration (FDA) Philadelphia
District, in cosponsorship with the
Society of Clinical Research Associates
(SoCRA) is announcing a public
workshop entitled: ‘‘FDA Clinical Trial
Requirements, Regulations, Compliance
and GCP.’’ This 2-day public workshop
is intended to provide information
about FDA clinical trial requirements to
the regulated industry.
Date and Time: The public workshop
will be held on October 21, 2009, from
8:30 a.m. to 5 p.m. and October 22,
2009, from 8:30 a.m. to 5 p.m.
Location: The public workshop will
be held at the Hyatt Regency Pittsburgh
International Airport, 1111 Airport
Blvd., Pittsburgh, PA 15231, 724–899–
1234 or 1–800–233–1234.
Attendees are responsible for their
own accommodations. To make
reservations at the Hyatt Regency Hotel,
contact the Hyatt Regency Hotel.
Contact: Marie Falcone, Food and
Drug Administration, U.S.
Customhouse, 200 Chestnut St., rm. 900,
Philadelphia, PA 19106, 215–717–3703,
FAX: 215–597–4660, e-mail:
marie.falcone@fda.hhs.gov.
Registration: You are encouraged to
register by October 19, 2009. The
SoCRA registration fees cover the cost of
facilities, materials, and breaks. Seats
are limited; please submit your
registration as soon as possible. Course
space will be filled in order of receipt
of registration. Those accepted in to the
course will receive confirmation.
Registration will close after the course is
filled. Registration at the site is not
guaranteed but may be possible on a
space available basis on the day of the
public workshop beginning at 8 a.m.
The cost of registration is as follows:
II. Selection Procedure
VerDate Nov<24>2008
Food and Drug Administration,
HHS.
Jkt 217001
PO 00000
Affiliation
Fee
FDA Employee
Government (Non-Member)
Frm 00048
Fmt 4703
Sfmt 4703
Fee Waived
$525.00
E:\FR\FM\26AUN1.SGM
26AUN1
43142
Federal Register / Vol. 74, No. 164 / Wednesday, August 26, 2009 / Notices
COST OF REGISTRATION—Continued
Affiliation
Fee
Non-Government (SoCRA
Member)
$575.00
Non-Government (Non
SoCRA Member)
$650.00
If you need special accommodations
due to a disability, please contact Marie
Falcone (see Contact) at least 7 days in
advance of the workshop.
Registration Instructions: To register,
please submit a registration form with
your name, affiliation, mailing address,
telephone, fax number, and e-mail
address, along with a check or money
order payable to ‘‘Socra.’’ Mail to:
SoCRA, 530 West Butler Ave., suite 109,
Chalfont, PA 18914. To register via the
Internet, go to https://www.socra.org/
html/FDA_Conference.htm. FDA has
verified the Web site address, but is not
responsible for subsequent changes to
the Web site after this document
publishes in the Federal Register).The
registrar will also accept payment by
major credit cards (VISA/MasterCard/
AMEX only). For more information on
the public workshop, or for questions on
registration, contact the Society of
Clinical Research Associates at 800–
762–7292 or 215–822–8644, FAX: 215–
822–8633, or e-mail:
SoCRAmail@aol.com.
The
public workshop helps fulfill the
Department of Health and Human
Services’ and FDA’s important mission
to protect the public health. The
workshop will provide those engaged in
FDA-regulated (human) clinical trials
with information on a number of topics
concerning FDA requirements related to
informed consent, clinical investigation
requirements, institutional review board
(IRB) inspections, electronic record
requirements, and investigator initiated
research. Topics for discussion include
the following:
• What FDA Expects in a
Pharmaceutical Clinical Trial;
• Adverse Event Reporting—Science,
Regulation, Error, and Safety;
• Part 11 Compliance—Electronic
Signatures;
• Informed Consent Regulations;
• IRB Regulations and FDA
Inspections;
• Keeping Informed and Working
Together;
• FDA Conduct of Clinical
Investigator Inspections;
• Meetings With FDA: Why, When,
and How;
• Investigator Initiated Research;
jlentini on DSKJ8SOYB1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Nov<24>2008
17:05 Aug 25, 2009
Jkt 217001
• Medical Device Aspects of Clinical
Research;
• Working With FDA’s Center for
Biologics Evaluation and Research; and
• The Inspection is Over—What
Happens Next? Possible FDA
Compliance Actions.
FDA has made education of the drug
and device manufacturing community a
high priority to help ensure the quality
of FDA-regulated drugs and devices.
The public workshop helps to achieve
objectives set forth in section 406 of the
FDA Modernization Act of 1997 (21
U.S.C. 393) which includes working
closely with stakeholders and
maximizing the availability and clarity
of information to stakeholders and the
public. The public workshop also is
consistent with the Small Business
Regulatory Enforcement Fairness Act of
1996 (Public Law 104–121), as outreach
activities by Government agencies to
small businesses.
Dated: August 18, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–20340 Filed 8–25–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Public Health
Informatics (BSC, NCPHI)
Correction: The notice was published
in the Federal Register on August 18,
2009 [Volume 74, Number 158] [page
41712]. The ‘‘Matters To Be Discussed’’
has been revised: The board will discuss
public health informatics issues related
to the H1N1 virus; CDC public health
informatics strategies and goals,
including future program activities; and
how the board can provide informatics
scientific input to CDC.
Contact Person for More Information:
Dr. Scott McNabb, National Center for
Public Health Informatics, CDC, 1600
Clifton Road, NE., Mailstop E–78,
Atlanta, Georgia 30333, Telephone (404)
498–6427, Fax (404) 498–6235.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the CDC
and the Agency for Toxic Substance and
Disease Registry.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Dated: August 18, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–20575 Filed 8–25–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary
and Alternative Medicine
Announcement of Wellness Workshop
ACTION:
Notice.
SUMMARY: The National Center for
Complementary and Alternative
Medicine (NCCAM) invites the research
community to participate in a workshop
focused on wellness.
The purpose of this workshop is to
review several measures of wellness,
identify their strengths and weaknesses,
and make recommendations on how
best to capture the construct. This
information will help NCCAM guide
development of questions for the 2012
National Health Interview Survey.
The Workshop will take place on
September 25, 2009. Those interested in
CAM research are particularly
encouraged to attend.
Background: The National Center for
Complementary and Alternative
Medicine (NCCAM) was established in
1999 with the mission of exploring
complementary and alternative healing
practices in the context of rigorous
science, training CAM researchers, and
disseminating authoritative information
to the public and professionals. NCCAM
funds research grants that explore the
science of CAM. For more information,
see https://nccam.nih.gov/grants/
whatnccamfunds/.
Participating: The public is invited to
attend and observe this workshop.
Those interested in attending are
required to RSVP via e-mail to Edward
Culhane Jr. at culhane@mail.nih.gov
with their name, affiliation, e-mail and
phone number. Space constraints limit
the number of attendees at this
workshop and participation will be on
a first come, first served basis. For more
information about what will be covered
at the workshop, see https://
nccam.nih.gov/news/events/.
FOR FURTHER INFORMATION CONTACT: To
request more information, visit the
NCCAM Web site at https://
nccam.nih.gov/news/events/, call 301–
594–3391 (Edward Culhane Jr.) or email at culhanee@mail.nih.gov.
E:\FR\FM\26AUN1.SGM
26AUN1
Agencies
[Federal Register Volume 74, Number 164 (Wednesday, August 26, 2009)]
[Notices]
[Pages 43141-43142]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20340]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Industry Exchange Workshop on Food and Drug Administration Drug
and Device Requirements; Public Workshop
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public workshop.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) Philadelphia District,
in cosponsorship with the Society of Clinical Research Associates
(SoCRA) is announcing a public workshop entitled: ``FDA Clinical Trial
Requirements, Regulations, Compliance and GCP.'' This 2-day public
workshop is intended to provide information about FDA clinical trial
requirements to the regulated industry.
Date and Time: The public workshop will be held on October 21,
2009, from 8:30 a.m. to 5 p.m. and October 22, 2009, from 8:30 a.m. to
5 p.m.
Location: The public workshop will be held at the Hyatt Regency
Pittsburgh International Airport, 1111 Airport Blvd., Pittsburgh, PA
15231, 724-899-1234 or 1-800-233-1234.
Attendees are responsible for their own accommodations. To make
reservations at the Hyatt Regency Hotel, contact the Hyatt Regency
Hotel.
Contact: Marie Falcone, Food and Drug Administration, U.S.
Customhouse, 200 Chestnut St., rm. 900, Philadelphia, PA 19106, 215-
717-3703, FAX: 215-597-4660, e-mail: marie.falcone@fda.hhs.gov.
Registration: You are encouraged to register by October 19, 2009.
The SoCRA registration fees cover the cost of facilities, materials,
and breaks. Seats are limited; please submit your registration as soon
as possible. Course space will be filled in order of receipt of
registration. Those accepted in to the course will receive
confirmation. Registration will close after the course is filled.
Registration at the site is not guaranteed but may be possible on a
space available basis on the day of the public workshop beginning at 8
a.m. The cost of registration is as follows:
Cost of Registration
------------------------------------------------------------------------
Affiliation Fee
------------------------------------------------------------------------
FDA Employee Fee Waived
------------------------------------------------------------------------
Government (Non-Member) $525.00
------------------------------------------------------------------------
[[Page 43142]]
Non-Government (SoCRA Member) $575.00
------------------------------------------------------------------------
Non-Government (Non SoCRA Member) $650.00
------------------------------------------------------------------------
If you need special accommodations due to a disability, please
contact Marie Falcone (see Contact) at least 7 days in advance of the
workshop.
Registration Instructions: To register, please submit a
registration form with your name, affiliation, mailing address,
telephone, fax number, and e-mail address, along with a check or money
order payable to ``Socra.'' Mail to: SoCRA, 530 West Butler Ave., suite
109, Chalfont, PA 18914. To register via the Internet, go to https://www.socra.org/html/FDA_Conference.htm. FDA has verified the Web site
address, but is not responsible for subsequent changes to the Web site
after this document publishes in the Federal Register).The registrar
will also accept payment by major credit cards (VISA/MasterCard/AMEX
only). For more information on the public workshop, or for questions on
registration, contact the Society of Clinical Research Associates at
800-762-7292 or 215-822-8644, FAX: 215-822-8633, or e-mail:
SoCRAmail@aol.com.
SUPPLEMENTARY INFORMATION: The public workshop helps fulfill the
Department of Health and Human Services' and FDA's important mission to
protect the public health. The workshop will provide those engaged in
FDA-regulated (human) clinical trials with information on a number of
topics concerning FDA requirements related to informed consent,
clinical investigation requirements, institutional review board (IRB)
inspections, electronic record requirements, and investigator initiated
research. Topics for discussion include the following:
What FDA Expects in a Pharmaceutical Clinical Trial;
Adverse Event Reporting--Science, Regulation, Error, and
Safety;
Part 11 Compliance--Electronic Signatures;
Informed Consent Regulations;
IRB Regulations and FDA Inspections;
Keeping Informed and Working Together;
FDA Conduct of Clinical Investigator Inspections;
Meetings With FDA: Why, When, and How;
Investigator Initiated Research;
Medical Device Aspects of Clinical Research;
Working With FDA's Center for Biologics Evaluation and
Research; and
The Inspection is Over--What Happens Next? Possible FDA
Compliance Actions.
FDA has made education of the drug and device manufacturing
community a high priority to help ensure the quality of FDA-regulated
drugs and devices. The public workshop helps to achieve objectives set
forth in section 406 of the FDA Modernization Act of 1997 (21 U.S.C.
393) which includes working closely with stakeholders and maximizing
the availability and clarity of information to stakeholders and the
public. The public workshop also is consistent with the Small Business
Regulatory Enforcement Fairness Act of 1996 (Public Law 104-121), as
outreach activities by Government agencies to small businesses.
Dated: August 18, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-20340 Filed 8-25-09; 8:45 am]
BILLING CODE 4160-01-S